This article was originally published in The Tan Sheet
Executive SummaryCapital raised from WellGen's most recent round of funding will reinforce its leadership position in the emerging field of nutrigenomics and functional foods, the New Brunswick, N.J.-based firm announces Oct. 29. Specifically, the funding will enable the firm to "advance its anti-obesity ingredient for functional foods, including the launch of a human study that has already received Institutional Review Board approval, and to conduct further studies of its recently patented product WG0401," company notes. WellGen received a patent for its WG0401 ingredient covering its use for arthritis, inflammation and cancer in July; the product was developed through nutrigenomics, the study of how nutrients affect gene expression (1"The Tan Sheet" July 16, 2007, In Brief)...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.